Misoprostol for induction of labor at term?
While oral misoprostol isn't superior to vaginal dinoprostone for induction of labor at term, it isn't inferior either. It doesn't lead to poorer health outcomes for women or their infants and offers a preferred route of administration.
While oral misoprostol isn't superior to vaginal dinoprostone for induction of labor at term, it isn't inferior either. It doesn't lead to poorer health outcomes for women or their infants and offers a preferred route of administration.
Researchers from Australia conducted a randomized, double-blind, placebo-controlled trial involving 741 women. They found no significant differences in the rates of vaginal birth not achieved in 24 hours (46% vs. 41.2%), cesarean section (22.7% vs. 26.6%), cesarean section for fetal distress (8.8% vs. 9.3%), or in uterine hyperstimulation with changes in fetal heart rate (0.8% vs. 1.6%). In addition, the women randomized to receive misoprostol reported a more positive birth experience.
Dodd JM, Crowther CA, Robinson JS. Oral misoprostol for induction of labour at term: randomised controlled trial. BMJ. 2006;332:509-513.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
